Literature DB >> 11578655

Differentiation therapy of human cancer: basic science and clinical applications.

M Leszczyniecka1, T Roberts, P Dent, S Grant, P B Fisher.   

Abstract

Current cancer therapies are highly toxic and often nonspecific. A potentially less toxic approach to treating this prevalent disease employs agents that modify cancer cell differentiation, termed 'differentiation therapy.' This approach is based on the tacit assumption that many neoplastic cell types exhibit reversible defects in differentiation, which upon appropriate treatment, results in tumor reprogramming and a concomitant loss in proliferative capacity and induction of terminal differentiation or apoptosis (programmed cell death). Laboratory studies that focus on elucidating mechanisms of action are demonstrating the effectiveness of 'differentiation therapy,' which is now beginning to show translational promise in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578655     DOI: 10.1016/s0163-7258(01)00132-2

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  77 in total

Review 1.  15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

Authors:  Sun Il Lee; Xiangsheng Zuo; Imad Shureiqi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway.

Authors:  Yan Li; Wei Yin; Xia Wang; Wenbo Zhu; Yijun Huang; Guangmei Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-06       Impact factor: 11.205

Review 3.  Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.

Authors:  Paul B Fisher; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Pankaj Gupta; Moira Sauane; Zao-zhong Su; Steven Grant; Paul Dent; David T Curiel; Neil Senzer; John Nemunaitis
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-23       Impact factor: 4.219

4.  Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1.

Authors:  Michael Papetti; Arthur I Skoultchi
Journal:  Mol Cancer Res       Date:  2007-10       Impact factor: 5.852

5.  mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.

Authors:  Dong-chul Kang; Rahul V Gopalkrishnan; Qingping Wu; Eckhard Jankowsky; Anna Marie Pyle; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

6.  Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion.

Authors:  Micheline J Moussalli; Yuanqing Wu; Xiangsheng Zuo; Xiu L Yang; Ignacio Ivan Wistuba; Maria G Raso; Jeffrey S Morris; Jessica L Bowser; John D Minna; Reuben Lotan; Imad Shureiqi
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

7.  IL-12 could induce monocytic tumor cells directional differentiation.

Authors:  Ting-Ting Ma; Bi-Tao Wu; Yan Lin; Hai-Yu Xiong; Qin Wang; Zi-Wei Li; Feng Cheng; Zhi-Guang Tu
Journal:  Mol Cell Biochem       Date:  2015-01-07       Impact factor: 3.396

8.  Identification and cloning of human polynucleotide phosphorylase, hPNPase old-35, in the context of terminal differentiation and cellular senescence.

Authors:  Magdalena Leszczyniecka; Dong-Chul Kang; Devanand Sarkar; Zao-Zhong Su; Matthew Holmes; Kristoffer Valerie; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-09       Impact factor: 11.205

9.  Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells.

Authors:  Elisabetta Ceni; Tommaso Mello; Mirko Tarocchi; David-W Crabb; Anna Caldini; Pietro Invernizzi; Calogero Surrenti; Stefano Milani; Andrea Galli
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

10.  Induction of S. cerevisiae filamentous differentiation by slowed DNA synthesis involves Mec1, Rad53 and Swe1 checkpoint proteins.

Authors:  Yi Wei Jiang; Christopher Minkyu Kang
Journal:  Mol Biol Cell       Date:  2003-10-17       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.